ESR1 and breast carcinoma: Moreover, our results demonstrate that HMGCS2 added to the steroid hormone receptor signature (ER-/PR-/AR+) identifies apocrine tumors from other breast cancer subtypes with greater sensitivity as compared to steroid receptor profile alone.